Novo Nordisk to reinforce its equity stake in Innate Pharma Marseille, France and Bagsværd, Denmark, 5 February 2014 Anti-NKG2A is a first-in-class therapeutic mAb that is Phase II ready NKG2A is a NK...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announces today the...

The private placement will be directed to specialized institutional investors, located mainly in the United-States It was launched after market close on November 15 Innate Pharma SA (the “Company” -...

MICA validated as a novel target for antibody drug development in solid tumors IPH43 program now aims at selection and optimization of the best development candidate Innate Pharma SA (the “Company” -...

Evidence for lirilumab single-agent activity in lymphoma Demonstration of enhanced efficacy of anti-CD20 antibodies when combined with lirilumab To be presented at ASH meeting, December 9, abstract...

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announces today that three posters on...

IPH4102 is a first-in-class drug candidate targeting KIR3DL2, a receptor specifically expressed by some rare forms of cancer It is developed in an orphan disease, cutaneous T-cell lymphomas, and...

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announces revenue of 6.8 million...

New site-specific conjugation technology for homogenous antibody-drug conjugates (ADCs) Provides further opportunities for portfolio expansion and partnering Innate Pharma SA (the “Company” - Euronext...

Nicolai Wagtmann, previously Vice-President R&D at Novo Nordisk A/S, generated and developed a portfolio of therapeutic antibodies for the treatment of cancer and inflammatory diseases François...